Italia markets closed

Aeterna Zentaris Inc. (AEZS)

NasdaqCM - NasdaqCM Prezzo in tempo reale. Valuta in USD.
Aggiungi a watchlist
2,1111+0,0311 (+1,50%)
In data: 12:52PM EDT. Mercato aperto.
Schermo intero
I prezzi di scambio non provengono da tutti i mercati
Chiusura precedente2,0800
Aperto2,0200
Denaro1,5400 x 200
Lettera2,6200 x 200
Min-Max giorno2,0200 - 2,1900
Intervallo di 52 settimane1,3600 - 3,3800
Volume44.448
Media Volume16.660
Capitalizzazione10,251M
Beta (5 anni mensile)N/D
Rapporto PE (ttm)N/D
EPS (ttm)-4,8100
Prossima data utili07 mag 2024 - 13 mag 2024
Rendimento e dividendo (futuro)N/D (N/D)
Data ex dividendoN/D
Stima target 1A15,00
  • GlobeNewswire

    Aeterna Zentaris to Participate at the Virtual Investor Ask the CEO Conference

    – Live moderated webcast with Klaus Paulini, Chief Executive Officer of Aeterna Zentaris on Wednesday, October 25th at 10:00 AM ET TORONTO, ONTARIO, Oct. 11, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna Zentaris will participate a

  • GlobeNewswire

    Aeterna Zentaris to Present at the H.C. Wainwright 25th Annual Global Investment Conference

    TORONTO, ONTARIO, Sept. 05, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today announced that Dr. Klaus Paulini, Chief Executive Officer of Aeterna, will present at the H.C. Wainwright 25th Annual Global Investment Conference being held September 11-13, 2023 in New York, NY in person and virtually. Dr. P

  • GlobeNewswire

    Aeterna Zentaris Reports Second Quarter 2023 Financial Results

    Ended the quarter with $42.2 million in cash, expected to fund operations into 2025Driving patient recruitment for Phase 3 DETECT trial for the diagnosis of Childhood Onset Growth Hormone Deficiency TORONTO, ONTARIO, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Aeterna Zentaris Inc. (NASDAQ: AEZS) (TSX: AEZS) (“Aeterna” or the “Company”), a specialty biopharmaceutical company developing and commercializing a diversified portfolio of pharmaceutical and diagnostic products, today reported its financial and o